Status:
COMPLETED
Effectiveness of Anti-VEGF Treatments in Wet AMD in Active Smokers
Lead Sponsor:
Brugmann University Hospital
Conditions:
Wet Age-related Macular Degeneration
Eligibility:
All Genders
18+ years
Brief Summary
" Wet Age-related Macular Degeneration (wet AMD)" is characterized by the appearance of new choroidal vessels. Several clinical studies have shown the effectiveness of intra-vitreous injections of ant...
Eligibility Criteria
Inclusion
- CHU Brugmann Hospital patients
- Patients who received three intra-vitreous injections of ranibizumab, aflibercept or bevacizumab 4 weeks apart as the first intra-vitreous treatment between January 2016 and December 2020.
- Visual acuity measured before the start of the injections (maximum 1 month) and after the series of three injections (4 to 8 weeks after the last injection)
- Patients whose smoking status is known and for whom the following history appears: hypertension, diabetes, taking anti-coagulants or anti-aggregants.
Exclusion
- Patients who have already received another intravitreal treatment in the past.
- Patients who have been treated with dynamic phototherapy before or at the same time as the injections.
Key Trial Info
Start Date :
November 10 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 28 2021
Estimated Enrollment :
148 Patients enrolled
Trial Details
Trial ID
NCT04685369
Start Date
November 10 2020
End Date
July 28 2021
Last Update
March 8 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Brugmann
Brussels, Belgium, 1020